Current Treatment Options for Latent Tuberculosis Infection

摘要: Treatment of latent tuberculosis infection (LTBI) is a key component in TB control strategies worldwide. However, as people with LTBI are neither symptomatic nor contagious, any screening decision should be weighed carefully against the potential benefit preventing active disease those who known to at higher risk and willing accept therapy for LTBI. This means that targeted approach desirable maximize cost effectiveness guarantee patient adherence. We focus on treatment populations increased developing TB, including candidates tumor necrosis factor-α blockers. In last 40 years, isoniazid (INH) has represented keystone across world. Although INH remains first therapeutic option, alternative treatments effective associated adherence economic savings available. Current recommendations, toxicity, compliance, issues discussed detail this review. A balanced relationship between healthcare provider could increase adherence, while cost-saving effectiveness, fewer side effects, shorter duration offered preferred.